As Growth in China Slows, Medtech Companies Remain Bullish

ARTICLE SUMMARY:

Growth in China has slowed considerably of late, but the country’s economic woes actually present some unique opportunities for well-positioned medtech companies, particularly those with established strategies aimed at localizing their China operations.

Although China is entering into a period of slower growth and economic uncertainty—heralded this summer by several weeks of extreme volatility in the country’s stock market—most of the top US multinational medical device companies appear to be weathering the storm well, with minimal impact on the bottom line thus far.

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.


Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to MedTech Strategist:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to MedTech Strategist
Subscribe to ELITE Strategist

Become an ELITE Strategist and unlock access to both MedTech Strategist and MTS Market Pathways.

Subscribe to Elite

Questions?

We're here to help! Please contact us at: